MISSOULA, Mont., Aug 22, 2005 (BUSINESS WIRE) -- Technical Sourcing International, Inc. (TSI) announced today that an abstract of a study using its Promilin ingredient was approved for oral presentation at the 4th Annual Scientific Meeting of the Canadian Society for Clinical Nutrition (CSCN), to be held September 8-10 in Montreal. The new study provides evidence that the patent-pending, proprietary extract of bioactive amino acids from fenugreek seed, which is an especially concentrated source of the amino acid-derivative 4-hydroxyisoleucine (4-OH-Ile), appears to cause a reduction in blood glucose levels in patients with metabolic syndrome X.
Previous studies have shown that Promilin has an effect on insulin utilization. Insulin resistance is one of the key contributing factors to the development of metabolic syndrome X, which encompasses a series of conditions including visceral obesity (fat in the abdominal area), elevated blood sugar, elevated triglycerides, low levels of HDL cholesterol and high blood pressure. According to the third National Health and Nutrition Examination Survey (NHANES), one in five Americans is affected by Syndrome X.
Entitled "The Study of Promilin (Fenugreek Extract) Therapy in Metabolic Syndrome X," the randomized, double-blind, parallel design, placebo-controlled trial sought to determine effective dose ranges of Promilin in subjects with metabolic syndrome X. It was authored by Dana Headapohl, M.D., who is the Director of Occupational Health at St. Patrick Hospital in Missoula, MT. Dr. Headapohl also served as the principal investigator for the project. The original research protocol was designed and authored by Whitney Whidhalm, Pharm D and Cindi Laukes, M.A., Clinical Research Manager for The Montana Neuroscience Institute in Missoula, MT. Research volunteers were followed by Pamela Meck, R.N., a research nurse at St. Patrick Hospital and Health Sciences Center in Missoula.
Forty subjects with the disorder were randomly divided into four groups, each of whom received an acute dose of either: placebo, 200 mg, 400 mg or 800 mg of Promilin. Following acute dosing with Promilin, the 400 mg group saw a 9.8% reduction in two hour blood glucose and an 18.3% reduction in the area under the curve, both of which showed some significance.
None of the other treatment groups showed significant differences between the initial and follow-up visits. The researchers were surprised that similar effects were not seen with the 800 mg group as with the 400 mg group, however they noted that the small sample size and the heterogenous nature of metabolic syndrome X could have been influencing factors. They called for further studies to explore the effectiveness of chronic dosing of Promilin.
The abstract is a perfect fit for the CSCN meeting, called "Nutrition in Health and Disease: Focus on Obesity and Gastrointestinal Disorders," as obesity increases insulin sensitivity and therefore contributes to the development of metabolic syndrome X. Abstracts submitted to CSCN were judged on the quality, originality and completeness of the work. Most of the abstracts approved were for poster presentations only. However, a select few, including Dr. Headapohl's Promilin abstract, were deemed "premier" abstract submissions and were approved for oral presentation.
About Technical Sourcing International, Inc.
Technical Sourcing International, Inc. (TSI) is a leading developer, producer, and marketer of nutraceutical ingredients to the dietary supplement, pharmaceutical, and food and beverage industries. Among the numerous botanical, marine, and natural product extracts, as well as synthesized compounds in its ingredient portfolio, the company also offers several trademarked consumer ingredient brands, including OSTIVONE(R), PROMILIN(R), PEAK ATP(TM), MSV 60(R), Ginkgo 24/6/5(TM) and PUREFLEX(R) Chondroitin Sulfate and Glucosamine. The company is based in Missoula, Montana, and can be reached at 406-549-9123 or www.tsiinc.com.